Agomab Therapeutics has been granted a US patent for AGMB-447, an inhaled small molecule drug targeting ALK5, currently in Phase 1b trials for idiopathic pulmonary fibrosis (IPF). This patent protects the drug's composition in the US until at least 2041, supporting Agomab's efforts to develop effective treatments for IPF, a serious lung disease. Positive early trial results in healthy subjects have been reported, with patient data expected later this year. AGMB-447 aims to offer a lung-specific anti-fibrotic therapy with minimal systemic exposure, potentially improving safety and efficacy for IPF patients.
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
